Inhaled sodium pyruvate improved FEV1 and decreased expired breath levels of nitric oxide in patients with chronic obstructive pulmonary disease

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 21, Issue 4, 2008, Pages 329-334

  Votto, John J ^a   Bowen, Janet B ^a   Barton, Randall W ^a   Thrall, Roger S ^a,b  

^a Hospital for Special Care New Britain   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Antioxidant; COPD; FEV1; NO; Pyruvate

Indexed keywords

NITRIC OXIDE; PLACEBO; PYRUVATE SODIUM;

AGED; ARTICLE; BREATHING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; SPIROMETRY;

ADMINISTRATION, INHALATION; AGED; AGED, 80 AND OVER; ANTIOXIDANTS; BREATH TESTS; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PYRUVIC ACID; SPIROMETRY; TIME FACTORS;

EID: 57149107864     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2007.0678     Document Type: Article

References (42)

1. Mallet RT, Sun J, Knott EM, Sharma AB, and Olivencia-Yurvati AH: Metabolic cardioprotection by pyruvate: recent progress. Exp Biol Med. 2005;230:4235-4443.
2. Zhou FQ: Pyruvate in the correction of intracellular acidosis: a metabolic basis as a novel superior buffer. Am J Nephrol. 2005;25:55-63.
3. Herz H, Blake DR, and Grootveld M: Multicomponent investigation of the hydrogen peroxide and hydroxyl radical scavenging antioxidant capacities of biofluids: the roles of endogenous pyruvate and lactate. Free Radic Res. 1997;26:19-35.
4. Giandomenico A, Cerniglia GE, Biaglow JE, Stevens CW, and Koch CJ: The importance of sodium pyruvate in assessing damage produced by hydrogen peroxide. Free Radic Biol Med. 1997;23:426-434.
5. O'Donnel-Tomey J, Nathan CF, Lanks K, DeBoer CJ, and de la Harpe J: Secretion of pyruvate in antioxidant defense of mammalian cells. J Exp Med. 1987;165:500-514.
6. Andrae U, Singh J, and Ziegler-Skylakakis K: Pyruvate and related alpha-ketoacids protect mammalian cells in culture against hydrogen peroxide-induced cytotoxicity. Toxicol Lett. 1985;28:93-98.
7. Varma SC, and Morris SM: Peroxide damage to the eye lens in vitro prevention by pyruvate. Free Radic Res Commun. 1988;4:283-290.
8. Nath KA, Enright H, Nutter L, Fischereder M, Zou JN, and Hebel RP: Effect of pyruvate on oxidant injury to isolated and cellular DNA. Kidney Int. 1994;45:166-176.
9. Brunkhorst R, and Mahiout, A: Pyruvate neutralizes peritoneal dyalysate cytoxicity: maintained integrity and proliferation of cultured human mesothelial cells. Kidney Int. 1995;48:177-181.
10. Shah SH: Role of reactive oxygen metabolites in experimental glomerular disease. Kidney Int. 1989;35:1093-1106.
11. Paller MS, Hoidal JR, and Ferris TP: Oxygen free radicals in ischemic acute renal failure in the rat. J Clin Invest. 1984;74:1156-1164.
12. Gupta SK, Rastogi S, Prakash J, Joshi S, Gupta, YK, Awor, L, and Verma SD: Anti-inflammatory activity of sodium pyruvate - a physiological antioxidant. Ind J Physiol Pharmacol. 2000;44:101-104.
13. Dijkstra U, Gabreels F, Joosetn E, Wevers R, Lamers K, Doesburg W, and Renier W: Friedrich's ataxia: intravenous pyruvate load to demonstrate a defect in pyruvate metabolism, Neurology. 1984;34:1493-1497.
14. Giannelli S Jr, McKenna JP, Bordiuk JM, Miller LD, and Jerome CR: Prevention of increased hemoglobin-oxygen affinity in open-heart operations with inosine- phosphate-pyruvate solution. Ann Thoracic Surg. 1976;21:386-396.
15. Campanacci L, Guarnieri GF, Faccini L, and Bellini G: Pyruvate tolerance test in chronic uremic patients. Nephron. 1973;10:232-237.
16. Levy SB, and Goldsmith LA: Sodium pyruvate treatment for hyperkeratotic disorders. South Med J. 1979;72:307-310.
17. Stanko RT, Reynolds HR, Lonchar KD, and Arch JE: Plasma lipid concentrations in hyperlipidemic patients consuming a high-fat diet supplemented with pyruvate for 6 wk. Am J Clin Nutr. 1992;56:950-954.
18. Jamieson, D: Oxygen toxicity and reactive oxygen metabolites in mammals. Free Radic Biol Med. 1989;7:87-108.
19. Baldwin SR, Grum CM, Boxer LA, Simon RH, Ketan LH, and Deuvall LJ: Oxidant activity in expired breath of patients with adult respiratory distress syndrome. Lancet 1986;8471:11-13.
20. Ward PA, Till GO, Hatherill JR, Annelsey TM, and Kunkel RG: Systemic complement activation, lung injury, and products of lipid peroxidation. J Clin Invest. 1985;76:517-527.
21. Perkowski SZ, Havill AM, Flynn JT, and Gee MH: Role of intrapulmonary release of eicosanoids and superoxide anion as mediators of pulmonary dysfunction and endothelial injury in sheep with intermittent complement activation. Circ Res. 1983;53:574-583.
22. Cross CE, Halliwell B, Borish ET, Pryor WA, Ames BN, Saul RL, McCord JM, and Harman D: Oxygen radicals and human disease. Ann Intern Med. 1987;107:526-545.
23. Bernard GR, Lucht WD, Niedermeyer ME, Snapper R, Ogletree ML, and Brigham KL: Effect of N-acetylcysteine on the pulmonary response to endotoxin in awake sheep and upon in vitro granulocycte function. J Clin Invest. 1984;73:1772-1784.
24. Townsley MI, Taylor GE, Korthuis RJ, and Taylor AE: Promethazine or DPPD pretreatment attenuates oleic acid-induced injury in isolated canine lungs. J Appl Physiol. 1985;59:39-46.
25. Brigham KL: Role of free radicals in lung injury. Chest. 1986;89:859-863.
26. Current estimates from the National Health Interview Survey United States, 1992: Data from the National Health Interview Survey. Series IO, No. 189 (January 1994).
27. McFadden ER, and Gilbert IA: Asthma. N Engl J Med. 1992;327:1928-1939.
28. Kharitonov SA, Yates D, Springall DR, Buttery L, Polak J, Robbins RA, Barnes PJ: Exhaled nitric oxide is increased in asthma. Chest. 1995;107:156S-157S.
29. Alving K, Weitzberg E, and Lundberg JM: Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J. 1993;6:1368-1370.
30. Maziak W, Loukides S, Culpitt S, Sullivan P, Kharitonov SA, and Barnes PJ: Exhaled nitric oxide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:998-1002.
31. Ansarin K, Chatkin JM, Ferreira IM, Gutierrez CA, Zamel N, and Chapman KR: Exhaled nitric oxide in stable chronic obstructive pulmonary disease; the relationship to pulmonary function abnormalities. Eur Respir J. 2001;17:934-938.
32. American Thoracic Society Documents. ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005. Am J Respir Crit Care Med. 2005;171:912-930.
33. Mason RJ, Broaddus VC, Murray JF, and Nadel JA: Murray and Nadel's Textbook of Respiratory Medicine. Elsevier Saunders, Philadelphia, PA; pp. 720, 2005.
34. 14, purity and stability. Anal Biochem. 1964;8:171-178.
35. Celli BR, MacNee W, and Committee Members: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-946.
36. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, and Maslen TK: Randomized, double blind, placebo controlled study of fluticasone proprionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Brit Med J. 2000;320:1297-1303.
37. Canonica GW: Treating asthma as an inflammatory disease. Chest. 2006;130:21-28.
38. National Asthma Education and Prevention Program. Expert panel report 3. Guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health, National Heart, Lung and Blood Institute; 2007. NIH Pre-Publication Copy. Available at http://www.nhlbi.nih.gov/guidelines/asthma/
39. Barnes PJ, and Pedersen S: Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992. Am Rev Respir Dis. 1993;148:S1-S26.
40. Gloire G, Legrand-Poels S, and Piette J: NF-kappa B activation by reactive oxygen species: fifteen years later. Biochem Pharmacol. 2006;72:493-505.
41. Bubici C, Papa S, Dean K, and Franzoso G: Mutual crosstalk between reactive oxygen species and nuclear factorkappa B: molecular basis and biological significance. Oncogene. 2006;25:6731-6748.
42. Lee Y-J, Kang I-J, Bünger R, and Kang, Y-H: Enhanced survival effect of pyruvate correlates MAPK and NF-kappa B activation in hydrogen peroxide treated human endothelial cells. J Appl Physiol. 2004;96:793-801.